- Previous Close
99.49 - Open
98.11 - Bid --
- Ask --
- Day's Range
96.50 - 100.99 - 52 Week Range
89.50 - 131.40 - Volume
102,594 - Avg. Volume
149,014 - Market Cap (intraday)
4.745B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
30.88 - EPS (TTM)
3.15 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
ZIM Laboratories Limited engages in the development, manufacture, and supply of generic pharmaceutical and nutraceutical products in India and internationally. The company provides its products in pre- formulation intermediates and finished formulations in the oral solid dosage forms, such as pellets, taste-masked powders, granules, tablets, capsules, dry syrup, and oral thin films. It offers therapeutics in the areas of urology, gastroenterology, antibiotics, anti-infectives, cardiovascular, central nervous system, NSAIDs/pain analgesics, and vitamins and supplements. The company was incorporated in 1984 and is based in Nagpur, India.
www.zimlab.in556
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: ZIMLAB.NS
View MorePerformance Overview: ZIMLAB.NS
Trailing total returns as of 2/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZIMLAB.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZIMLAB.NS
View MoreValuation Measures
Market Cap
4.85B
Enterprise Value
5.80B
Trailing P/E
31.58
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
2.00
Enterprise Value/Revenue
1.54
Enterprise Value/EBITDA
11.75
Financial Highlights
Profitability and Income Statement
Profit Margin
4.69%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
3.82B
Net Income Avi to Common (ttm)
179.18M
Diluted EPS (ttm)
3.15
Balance Sheet and Cash Flow
Total Cash (mrq)
98.84M
Total Debt/Equity (mrq)
46.82%
Levered Free Cash Flow (ttm)
--